Advancing Allogeneic CD19 Targeting Strategies to Enable Reliable Immune Reset in Autoimmune Disease

1:30 pm - Wednesday 2nd December 2026

  • Presenting preclinical data demonstrating B-cell targeting in SLE
  • Exploring allogeneic off-the-shelf approaches to improve scalability
  • Outlining strategies to translate preclinical findings into clinical development

Speakers:

Senior R&D Manager
Glycostem Therapeutics